Kangmei Pharma | 600518 - Sales Revenues

Stock Price
1.59
Daily Change
-0.02 -1.24%
Monthly
-9.14%
Yearly
-20.90%
Q2 Forecast
1.59

Kangmei Pharma reported CNY1.37B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Avita Medical AUD 17.61M 805K Dec/2025
Cspc Pharmaceutical CNY 6.11B 502.75M Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Genomma Lab Internacional MXN 4.17B 150M Mar/2026
Hypermarcas BRL 2.02B 217.07M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
IQVIA Holdings USD 4.15B 210M Mar/2026
Jiangsu Hengrui CNY 8.14B 300M Mar/2026
Kangmei Pharma CNY 1.37B 101.16M Sep/2025
Moderna USD 389M 289M Mar/2026
Organon & Co USD 1.46B 50M Mar/2026
Revvity USD 711M 61.06M Mar/2026
Sh Fosun Pharma CNY 10.07B 260M Dec/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Viatris USD 3.52B 180M Mar/2026
Wuxi Apptec CNY 12.6B 160M Dec/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026
Zhangzhou Pientzehuang Pharmaceutical CNY 2.72B 837.63M Mar/2026